Compound Profiles
CJC-1295 (without DAC)
Short-Acting Growth Hormone Releasing Hormone Analog
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
HGH
Human Growth Hormone | Somatropin
Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation.
Combined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take CJC-1295 (without DAC) with HGH?
Yes, but with caution. Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.
Is CJC-1295 (without DAC) and HGH safe together?
Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, estrogenic, insulin disrupting, teratogenic. Monitor accordingly.
What are the interactions between CJC-1295 (without DAC) and HGH?
Both CJC-1295 (without DAC) and HGH can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.
How should I time CJC-1295 (without DAC) and HGH?
CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and HGH has a half-life of 3-4 hours (SC), 20-30 minutes (IV). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.